



Programme

Thursday 8th September 2016
The Marriott, Copenhagen, Denmark

Ophthalmology Futures European Forum 2016

Dear Colleagues,

Welcome to Ophthalmology Futures European Forum 2016. After successful meetings in Milan, Amsterdam, London and Barcelona, as well as our inaugural Asian Forum in Tokyo, we are delighted to be hosting our fifth European Forum in Copenhagen.

Each Forum aims to present new perspectives with regard to innovation in the ophthalmic sector. This meeting will focus on advances in cataract and refractive surgery, imaging, pharma, drug delivery, glaucoma and retinal disease. We hope that you will enjoy the meeting format and gain inspiration from the company presentations and timely panel discussions which highlight the breadth of innovation and investment in the field.

Ophthalmology Futures aims to provide a platform for communication for all professionals involved in ocular health. The panel sessions at this our sixth meeting will address the impact of recent technological advancements in eyecare, corporate strategies to promote innovation and growth, important regulatory issues and strategic partnerships within the ophthalmology sector throughout Europe and other regions of the world.

We should like to take this opportunity to thank our advisory board, programme committee, corporate presenters, sponsors and eminent faculty who take part in the panel discussions for their invaluable support and assistance.

The Ophthalmology Futures Team



Vision Futures Limited, London, UK registered in England No: 8125858



Ophthalmology Futures European Forum 2016 Programme

07:00 Registration

07:45-08:00 Introduction and Welcome

Co-Chairs: **Keith Barton** Consultant Ophthalmologist, Moorfields Eye Hospital, UK

Kuldev Singh Professor of Ophthalmology and Director of Glaucoma Service, Stanford, USA

08:00-08:30 Panel 1: AMD – is the pipeline dry?

Chair: **Pravin Dugel** Managing Partner, Retinal Consultants of Arizona, USA

Panellists: **Eugene de Juan** Founder, ForSight Labs and Jean Kelly Stock Distinguished Chair in Ophthalmology, University of California, San Francisco, USA

Anat Loewenstein Vice Dean, Sackler Faculty of Medicine, Tel Aviv University and Chairman of Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Israel

José-Alain Sahel Director, Vision Institute and Professor of Ophthalmology at Pierre and Marie Curie University Medical School, Paris; and Cumberlege Professor of Biomedical Science, University College London, UK

Andreas Wenzel Translational Medical Clinical Science Director, Novartis Institutes for BioMedical Research (NIBR), Switzerland

08:30-09:30 Company Presentations 1

Co-Chairs: **Anat Loewenstein** Vice Dean, Sackler Faculty of Medicine, Tel Aviv University and Chairman of Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Israel

Keith Barton Consultant Ophthalmologist, Moorfields Eye Hospital, UK

08:30-08:37 Company: **Apellis**
Cedric Francois Chief Executive Officer

08:37-08:44 Company: **Second Sight**
Gregoire Cosendai Vice President, Europe

08:44-08:51 Company: **Salutaris Medical Devices™**
Dr Laurence Marsteller Chief Executive Officer

08:51-08:58 Company: **Cassini**
Jeroen Cameraat Chief Executive Officer i-Optics

08:58-09:05 Company: **Kali Care**
Sina Fateh Founder and Chief Executive Officer

09:05-09:12 Company: **Aerie Pharmaceuticals Inc.**
John Thygesen Associate Professor, Copenhagen University Hospital

09:12-09:19 Company: **NightstaRx**
David Fellows Chief Executive Officer

09:19-09:30 Summary

09:30-10:00 Panel 2: Why is gene therapy not yet in the DNA of big pharma

- Chair:** **José-Alain Sahel** Director, Vision Institute and Professor of Ophthalmology at Pierre and Marie Curie University Medical School, Paris; and Cumberlege Professor of Biomedical Science, University College London, UK
- Panellists:** **Simon Chandler** Senior Director, Clinical Research and Regulatory Operations, Ora Inc., UK
Vivian Choi Head of Gene Therapy Research, US Research and Non-clinical Development, Shire Pharmaceuticals, USA
Marc de Smet Chief Medical Officer, PRECEYES B.V, Switzerland
David Fellows Chief Executive Officer, NightstaRx, UK
Canwen Jiang Head of Global Clinical Development, Alcon, USA
Rogério Vivaldi Chief Commercial Officer, Spark Therapeutics, USA

10:00-10:30 Panel 3: Imaging – OCT angiography

- Chair:** **Frank Holz** Director and Chairman, Universitäts-Augenklinik Bonn, University of Bonn, Germany
- Panellists:** **Eugene de Juan** Founder, ForSight Labs and Jean Kelly Stock Distinguished Chair in Ophthalmology, University of California, San Francisco, USA
Pravin Dugel Managing Partner, Retinal Consultants of Arizona, USA
Ralf Kuschnereit Senior Vice President, Ophthalmic Systems Division, Carl Zeiss Meditec AG, Germany
Tien Yin Wong Senior Consultant, Retina Centre, Singapore National Eye Centre, Singapore

10:30-10:55 Coffee Break

10:55-12:10 Company Presentations 2

- Co-Chairs:** **Julian Stevens** Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, UK
Kuldev Singh Professor of Ophthalmology and Director of Glaucoma Service, Stanford, USA
- 10:55-11:02** Company: **Intelon Optics Inc.**
Dominik Beck President and Chief Executive Officer
- 11:02-11:09** Company: **Avedro**
Rajesh Rajpal Chief Medical Officer
- 11:09-11:16** Company: **Allotex**
Michael Mrochen Founder and Chief Executive Officer, IROC Science to Innovation
- 11:16-11:23** Company: **EyeYon Medical**
Nahum Ferera Chief Operating Officer
- 11:23-11:30** Company: **Altacor Ltd.**
Francesca E Crawford Chief Executive Officer
- 11:30-11:37** Company: **Mynosys Inc.**
John N Hendrick President and Chief Executive Officer
- 11:37-11:44** Company: **Z Lens LLC**
Paul M. Beer Founder and Chief Executive Officer
- 11:44-11:51** Company: **LensGen Inc.**
Ramgopal Rao Chief Executive Officer
- 11:51-11:58** Company: **AcuFocus Inc., USA**
Nicholas Tarantino Chief Clinical and Regulatory Officer, Head R&D
- 11:58-12:10** **Summary**

12:10-12:40 Panel 4: Trifocal and extended depth of focus

- Chair:** **Gerd Auffarth** Chairman, Department of Ophthalmology, University of Heidelberg, Germany
- Panellists:** **Alan Crandall** John A. Moran Presidential Professor, Val A. and Edith D. Green Presidential Endowed Chair, Senior Vice Chair, Director of Glaucoma and Cataract, Co-Director, Moran Outreach Division, USA
Karlheinz Rein Vice President, Product Marketing Cataract and Retina Surgery, Carl Zeiss Meditec AG, Germany
MK Raheja Global Head, Corneal and Cataract Research and Development, Abbott, USA
Sunil Shah Consultant Ophthalmologist, Birmingham Children's Hospital and Honorary Consultant, Honorary Professor, The University of Ulster, UK
Nicholas Tarantino Chief Clinical and Regulatory Officer, Head R&D, Acufocus Inc., USA
Ahmet Tezel Vice President, IOL R&D, Alcon, USA

12:40-13:40 Lunch

13:40-14:10 Panel 5: Tales around the campfire: Fireside chat with leading Venture Capitalists

- Chair:** **Naveed Siddiqi** Partner, Edmond de Rothschild Investment Partners, UK
- Panellists:** **Emmett Cunningham** Partner, Clarus Ventures LLC, USA
Thomas Dyrberg Managing Partner, Novo Ventures, Denmark
Steven Fang Partner, CapBridge, Singapore
Johan Kördel Senior Partner, Lundbeckford Ventures, Denmark
Bobby Soni Director, Healthcare Ventures, Imperial Innovations, UK

14:10-14:40 Panel 6: Dry Eye: Will new science lubricate the markets?

- Co-Chairs:** **Leonard Borrmann** Divisional Vice President, Research and Development, Abbott, USA
Alex Shortt Wellcome Trust Fellow, University College London, Honorary Consultant Ophthalmologist, Cornea and External Disease, Moorfields Eye Hospital, UK
- Panellists:** **Eric Carlson** Head of Strategic Operations and Planning, Alcon Research Labs Inc., USA
Seph Jensen Chief Executive Officer, TearLab Corporation, USA
George Ousler Vice President, Ora Inc., USA
Calvin Roberts Executive Vice President and Chief Medical Officer, Bausch+Lomb, USA
Baldo Scassellati Sforzolini Senior Vice President of Clinical Development, Allergan, USA
Amir Shojaei Vice President, Global Development lead, Ophthalmology and Transplant Medicine, Shire Pharmaceuticals Inc., USA

14:40-15:20 Company Presentations 3

- Chair:** **Donald Budenz**, Professor and Chairman, Department of Ophthalmology, University of North Carolina at Chapel Hill, USA
- 14:40-14:47** Company: **InnFocus Inc.**
Russ Trenary President and Chief Executive Officer
- 14:47-14:54** Company: **ALeyeGN Technologies LLC**
Michael Ballard President and Chief Executive Officer
- 14:54-15:03** Company: **Ivantis Inc.**
Dave Van Meter President and Chief Executive Officer
- 15:03-15:10** Company: **AQ BioMed Inc.**
Jim Kasic President and Chief Executive Officer
- 15:10-15:20** **Summary**

15:20-15:50 Coffee Break

15:50-16:20 Panel 7: MIGS - European Market Access

- Chair:** **Keith Barton** Consultant Ophthalmologist, Moorfields Eye Hospital, UK
- Panellists:** **Leon Au** Consultant Ophthalmologist, Manchester Royal Eye Hospital, UK
Frank Ender Director Market Access Surgical, Europe, Middle East and Africa, Alcon Management SA, Switzerland
Tim Kelleher Director, Eye Innovation Consultants, Ireland
Greg Kunst Director, Global Market Access and New Business Planning, Glaukos Corporation, USA
Alexander Natz Director General Europe and Attorney at Law, Novacos Rechtsanwälte, Brussels
Rishi Rattan International Market Access Director, Eye Care, Allergan, UK

16:20-16:50 Panel 8: Capsule-centred IOLs

- Chair:** **Marie-José Tassignon** Professor and Head of Department of Ophthalmology, Antwerp University Hospital, Belgium
- Panellists:** **Alan Crandall** John A. Moran Presidential Professor, Val A. and Edith D. Green Presidential Endowed Chair, Senior Vice Chair, Director of Glaucoma and Cataract, Co-Director, Moran Outreach Division, USA
Boris Malyugin Chief of Department of Cataract and Implant Surgery and Deputy Director General, S.Fyodorov Eye Microsurgery Complex State Institution, Russia
Samuel Masket Clinical Professor of Ophthalmology, Geffen School of Medicine, UCLA, USA
Paul Rosen Consultant Ophthalmic Surgeon, Oxford Radcliffe Hospital NHS Trust and Senior Lecturer, University of Oxford, UK
Julian Stevens Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, UK

16:50-17:20 Panel 9: A View from the Top in 2016 - Corporate CEOs


- Chair:** **James V. Mazzo** Global President Ophthalmic Devices, Carl Zeiss Meditec, USA
- Panellists:** **Mike Ball** Chief Executive Officer, Alcon, USA
Ludwin Monz President and Chief Executive Officer, Carl Zeiss Meditec AG, Germany
Flemming Ørnskov Chief Executive Officer, Shire Plc, USA
Naveed Shams President and Chief Executive Officer, Santen Inc., USA

17:20-18:30 The Shark Tank

See overleaf

18:30-18:40 Thank you and closing remarks from Keith Barton and Kuldev Singh

18:40-20:30 Cocktail Reception



Save the date

Ophthalmology Futures Asian Forum will be held on the 28th of February 2017 at the Pan Pacific Hotel, Singapore.

Visit ophthalmology-futures.com for further information and updates.

Also, please visit our LinkedIn and Facebook groups for up to date discussions around Ophthalmology all year round.



THIS IS YOUR
OPENING.

Make a once-in-a-lifetime difference with the safe MIGS procedure for cataract patients with glaucoma.



The complete procedure.

800.GLAUKOS (452.8567) Glaukos.com

iStent[®]
TRABECULAR
MICRO-BYPASS
STENT SYSTEM

INDICATION FOR USE. The iStent[®] Trabecular Micro-Bypass Stent (Models GTS100R and GTS100L) is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication. **CONTRAINDICATIONS.** The iStent[®] is contraindicated in eyes with primary or secondary angle closure glaucoma, including neovascular glaucoma, as well as in patients with retrolental tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. **WARNINGS.** Gonioscopy should be performed prior to surgery to exclude PAS, rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. The iStent[®] is MR-Conditional meaning that the device is safe for use in a specified MR environment under specified conditions, please see label for details. **PRECAUTIONS.** The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the iStent[®] has not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, chronic inflammation, or an abnormal anterior segment, in pseudophakic patients with glaucoma, in patients with pseudoxfoliative glaucoma, pigmentary, and uveitic glaucoma, in patients with unmedicated IOP less than 22 mmHg or greater than 36 mmHg after "washout" of medications, or in patients with prior glaucoma surgery of any type including argon laser trabeculoplasty, for implantation of more than a single stent, after complications during cataract surgery, and when implantation has been without concomitant cataract surgery with IOL implantation for visually significant cataract. **ADVERSE EVENTS.** The most common post-operative adverse events reported in the randomized pivotal trial included early post-operative corneal edema (8%), BCVA loss of ≥ 1 line at or after the 3 month visit (7%), posterior capsular opacification (6%), stent obstruction (4%) early post-operative anterior chamber cells (3%) and early post-operative corneal abrasion (3%). Please refer to Directions for Use for additional adverse event information. **CAUTION:** Federal law restricts this device to sale by, or on the order of, a physician. Please reference the Directions for Use labeling for a complete list of contraindications, warnings, precautions, and adverse events.

©2016 Glaukos Corporation. Glaukos and iStent are registered trademarks of Glaukos Corporation. 400-0285-2016-US Rev. 0

Ophthalmology Futures European Forum 2017

Save the date
5th October 2017
Lisbon, Portugal

Keep up to date
ophthalmology-futures.com

Agenda

The Shark Tank

Moderator

Keith Barton

Consultant Ophthalmologist,
Moorfields Eye Hospital, UK

The Sharks

Laurent Attias

Senior Vice President, Head of
Strategy, BD&L and Market Access,
Alcon, USA

Thomas Dyrberg

Managing Partner,
Novo Ventures, Denmark

James V. Mazzo

Global President Ophthalmic Devices,
Carl Zeiss Meditec, USA

Jane Rady

Divisional Vice President, Business
Development, Abbott, USA

Calvin Roberts

Executive Vice President and Chief
Medical Officer, Bausch+Lomb, USA

The Prey

| | |
|-------------|--|
| 17:20-17:30 | Introduction |
| 17:30-17:45 | Medicem – Eugen Chiceviç Chief Executive Officer |
| 17:45-18:00 | Implandata Ophthalmic Products GmbH – Max Ostermeier Managing Director |
| 18:00-18:15 | Elasmogen – Caroline Barelle, Elsamogen Ltd. Chief Executive Officer |
| 18:15-18:30 | The Vote |



List of Speakers and Affiliations

- **Laurent Attias**
Senior Vice President, Head of Strategy, BD&L and Market Access, Alcon, USA
- **Leon Au**
Consultant Ophthalmologist, Manchester Royal Eye Hospital, UK
- **Gerd Auffarth**
Chairman, Department of Ophthalmology, University of Heidelberg, Germany
- **Mike Ball**
Chief Executive Officer, Alcon, USA
- **Keith Barton**
Consultant Ophthalmologist, Moorfields Eye Hospital, UK
- **Leonard Borrmann**
Divisional Vice President, Research and Development, Abbott, USA
- **Donald Budenz**
Professor and Chairman, Department of Ophthalmology, University of North Carolina at Chapel Hill, USA
- **Eric Carlson**
Head of Strategic Operations and Planning, Alcon Research Labs Inc., USA
- **Simon Chandler**
Senior Director, Clinical Research and Regulatory Operations, Ora Inc., UK
- **Vivian Choi**
Head of Gene Therapy Research, US Research and Non-clinical Development, Shire Pharmaceuticals, USA
- **Alan Crandall**
John A. Moran Presidential Professor, Val A. and Edith D. Green Presidential Endowed Chair, Senior Vice Chair, Director of Glaucoma and Cataract, Co-Director, Moran Outreach Division, USA
- **Emmett Cunningham**
Partner, Clarus Ventures LLC, USA
- **Eugene de Juan**
Founder, ForSight Labs and Jean Kelly Stock Distinguished Chair in Ophthalmology, University of California, San Francisco, USA
- **Marc de Smet**
Chief Medical Officer, PRECEYES B.V, Switzerland
- **Pravin Dugel**
Managing Partner, Retinal Consultants of Arizona, USA
- **Thomas Dyrberg**
Managing Partner, Novo Ventures, Denmark
- **Frank Ender**
Director Market Access Surgical Europe, Middle East and Africa, Alcon Management SA, Switzerland
- **Steven Fang**
Partner, CapBridge, Singapore
- **Sina Fateh**
Founder and Chief Executive Officer, Kali Care, USA
- **David Fellows**
Chief Executive Officer, NightstaRx, UK
- **Frank Holz**
Director and Chairman, Universitäts-Augenklinik Bonn, University of Bonn, Germany
- **Seph Jensen**
Chief Executive Officer, TearLab Corporation, USA
- **Canwen Jiang**
Head of Global and Clinical Development, Alcon, USA
- **Tim Kelleher**
Director, Eye Innovation Consultants, Ireland
- **Johan Kördel**
Senior Partner, Lundbeckford Ventures, Denmark
- **Greg Kunst**
Director, Global Market Access and New Business Planning, Glaukos Corporation, USA
- **Ralf Kuschnereit**
Senior Vice President, Ophthalmic Systems Division, Carl Zeiss Meditec AG, Germany
- **Anat Loewenstein**
Vice Dean, Sackler Faculty of Medicine, Tel Aviv University and Chairman of Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Israel
- **Boris Malyugin**
Chief of Department of Cataract and Implant Surgery and Deputy Director General, S.Fyodorov Eye Microsurgery Complex State Institution, Russia



- **Samuel Masket**
Clinical Professor of Ophthalmology, Geffen School of Medicine, UCLA, USA
- **James V. Mazzo**
Global President Ophthalmic Devices, Carl Zeiss Meditec, USA
- **Ludwin Monz**
President and Chief Executive Officer, Carl Zeiss Meditec AG, Germany
- **Alexander Natz**
Director General, Europe and Attorney at Law, Novacos Rechtsanwälte, Brussels
- **Flemming Ørnskov**
Chief Executive Officer, Shire Plc, USA
- **George Ousler**
Vice President, Ora Inc., USA
- **Jane Rady**
Divisional Vice President, Business Development, Abbott, USA
- **MK Raheja**
Global Head, Corneal and Cataract Research and Development, Abbott, USA
- **Rishi Rattan**
International Market Access Director, Eye Care, Allergan, UK
- **Karlheinz Rein**
Vice President, Product Marketing Cataract and Retina Surgery, Carl Zeiss Meditec AG, Germany
- **Calvin Roberts**
Executive Vice President and Chief Medical Officer, Bausch+Lomb, USA
- **Paul Rosen**
Consultant Ophthalmic Surgeon Oxford Radcliffe Hospital NHS Trust and Senior Lecturer, University of Oxford, UK
- **José-Alain Sahel**
Director, Vision Institute and Professor of Ophthalmology at Pierre and Marie Curie University Medical School, Paris; and Cumberlege Professor of Biomedical Science, University College London, UK
- **Baldo Scassellati Sforzolini**
Senior Vice President of Clinical Development, Allergan, USA
- **Sunil Shah**
Consultant Ophthalmologist, Birmingham Children's Hospital and Honorary Consultant, Honorary Professor, The University of Ulster, UK
- **Naveed Shams**
President and Chief Executive Officer, Santen Inc., USA
- **Amir Shojaei**
Vice President, Global Development lead, Ophthalmology and Transplant Medicine, Shire Pharmaceuticals Inc., USA
- **Alex Shortt**
Wellcome Trust Fellow, University College London, and Honorary Consultant Ophthalmologist, Cornea and External Disease, Moorfields Eye Hospital, UK
- **Naveed Siddiqi**
Partner, Edmond de Rothschild Investment Partners, UK
- **Kuldev Singh**
Professor of Ophthalmology and Director of Glaucoma Service, Stanford, USA
- **Bobby Soni**
Director, Healthcare Ventures, Imperial Innovations, UK
- **Julian Stevens**
Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, UK
- **Nicholas Tarantino**
Chief Clinical and Regulatory Officer, Head R&D, Acufocus Inc., USA
- **Marie-José Tassignon**
Professor and Head of Department of Ophthalmology, Antwerp University Hospital, Belgium
- **Ahmet Tezel** Vice President, IOL R&D, Alcon, USA
- **Rogério Vivaldi**
Chief Commercial Officer, Spark Therapeutics, USA
- **Andreas Wenzel**
Translational Medical Clinical Science Director, Novartis Institutes for BioMedical Research (NIBR), Switzerland
- **Tien Yin Wong**
Senior Consultant, Retina Centre, Singapore National Eye Centre, Singapore

Mission Statement

An Ophthalmologist driven forum of corporate leaders, financiers, regulators, clinicians and scientists gathered to facilitate innovative ophthalmic product development and improve eye care delivery.

Supporting improved ocular health.

“A meeting where we bring together innovators, ophthalmologists, venture capitalists, pharmaceutical and device manufacturers as well as regulators and market analysts.”

Kuldev Singh, Professor of Ophthalmology and Director of Glaucoma Service, Stanford

Supported Charities

